ArticleFrontiers in endocrinology2025
The association between glutathione reductase and postmenopausal osteoporosis: a retrospective study.
Article in Frontiers in endocrinology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Targeting Oxidative Stress in Insulin-Resistant Postmenopausal Women: Effects of Resveratrol and Vitamin C on Oxidative Damage and Antioxidant Defenses in a Randomized Clinical Trial.Antioxidants (Basel, Switzerland) · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Oxidative stress is a common pathological condition in postmenopausal osteoporosis. Glutathione reductase, an antioxidant enzyme, plays a critical role in the body's antioxidant defense system. However, the relationship between glutathione reductase and postmenopausal osteoporosis remains unclear. This study aims to explore the association between glutathione reductase and postmenopausal osteoporosis. Methods: This study retrospectively analyzed hospitalized postmenopausal women aged over 45 years from China between January 1, 2020, and April 15, 2025. The cases were divided into the osteoporosis group (OP group, T ≤ -2.5) and the non-osteoporosis group (non-OP group, T > -2.5). Initially, independent-samples t-tests were performed to compare differences in continuous variables between the two groups. Subsequently, binary logistic regression was conducted to identify potential predictors, followed by variable selection using the least absolute shrinkage and selection operator (LASSO) regression. The selected variables were then incorporated into a multivariable logistic regression model to determine independent risk factors. Finally, the predictive performance of the model was evaluated using receiver operating characteristic (ROC) curves, concordance index (C-index), calibration curves, and decision curve analysis (DCA). Results: A total of 401 patients were enrolled in this study, with 149 in the non-OP group and 252 in the OP group. The OP group showed lower BMI, lumbar spine (L1-L4), femoral BMD, and hip BMD compared to the non-OP group (P < 0.05). The OP group had higher age, adenosine deaminase (ADA), and glutathione reductase (GR) levels than the non-OP group (P < 0.05). ROC analysis revealed that the area under the curve for GR was 0.604 (95% CI: 0.556-0.662), with a critical value of 55.8 U/L (P < 0.05). Binary logistic regression and LASSO regression analyses demonstrated that GR ≥ 55.8 U/L was a risk factor for postmenopausal osteoporosis. Conclusion: GR are significantly associated with postmenopausal osteoporosis, and GR ≥ 55.8 U/L is an important risk factor for postmenopausal osteoporosis.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.